Pfizer: European Commission Approves TALZENNA for Patients With Inherited BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
June 21, 2019
June 21, 2019
NEW YORK, June 21 -- Pfizer, a pharmaceutical company, issued the following news release:
* * *
- Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer
* * *
Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA(R) (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA) . . .
* * *
- Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer
* * *
Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA(R) (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA) . . .